

Inna Viktorova

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1786331/inna-viktorova-publications-by-citations.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9
papers

1,686
citations

6
h-index

16
g-index

16
ext. papers

2,320
ext. citations

8.5
avg, IF

3.74
L-index

#	Paper	IF	Citations
9	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018, 379, 2097-2107	59.2	1277
8	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2019, 7, 618-628	18.1	120
7	Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. <i>Lancet, The</i> , 2019, 394, 1169-1180	40	106
6	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7	4.9	72
5	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. <i>European Journal of Heart Failure</i> , 2019, 21, 921-929	12.3	53
4	Prevalence, Awareness, Treatment and Control of Hypertension in Russian Federation (Data of Observational ESSERF-2 Study). <i>Rational Pharmacotherapy in Cardiology</i> , 2019, 15, 450-466	0.5	52
3	The ESSE-RF2 epidemiological study in the Omsk Region: organization issues and the population response. <i>Profilakticheskaya Meditsina</i> , 2019, 22, 85	0.5	3
2	Joint hypermobility in association with osteoarthritis: A familial case. <i>Profilakticheskaya Meditsina</i> , 2017, 20, 42	0.5	
1	NON-ADHERENT BEHAVIOR IN PATIENTS WITH ANXIETY AND HYPERTENSION: FOCUS ON NON-PHARMACOLOGICAL TREATMENT AS A METHOD TO INCREASE COMPLIANCE. <i>Rational Pharmacotherapy in Cardiology</i> , 2016, 12, 661-668	0.5	